WeVote
Log In

Bill

Bill

H 1296

An Act to protect 340B providers

194th Legislature (2025-2026) Introduced by Sean Reid and 1 co-sponsor

Massachusetts bill to protect 340B drug program providers from manufacturer restrictions, ensuring healthcare systems can maximize pharmaceutical discounts for patient care.

Accompanied a new draft, see H4495
0
WeVote Research Nonpartisan
Bill Summary · H 1296

Legislative bill overview

H 1296 seeks to protect hospitals and healthcare providers participating in the federal 340B drug pricing program, which allows covered entities to purchase outpatient drugs at significant discounts. The bill addresses concerns about manufacturer restrictions, audit practices, or other compliance challenges that 340B providers face while operating under the program's requirements.

Why is this important

The 340B program saves participating hospitals and safety-net providers millions annually on pharmaceutical costs, allowing them to reinvest savings into patient care, uncompensated care, and community health services. Protection measures could ensure program viability for Massachusetts healthcare systems serving low-income and uninsured patients, though the specific protections remain unclear from available legislative history.

Potential points of contention

  • Manufacturer concerns: Pharmaceutical manufacturers may argue that expanded provider protections undermine their ability to prevent 340B drug diversion or non-qualifying patient access, potentially increasing costs they absorb
  • Regulatory clarity: Unclear whether protections conflict with existing federal 340B program rules administered by HRSA, potentially creating state-federal legal tensions
  • Definition ambiguity: The bill's specific protective mechanisms aren't detailed in available materials, making it difficult to assess whether protections are appropriately tailored or overly broad

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.